Head-to-head · Cost-Efficiency Index
Gimme Care vs Ro
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Gimme Care
Budget-conscious shoppers who want both molecules disclosed, nationwide access, and pharmacy verification without a premium.
Visit Gimme CareRo
People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Visit RoThe verdict
Gimme Care takes it, leading the Cost-Efficiency Index 87 to 84. Low, fully-disclosed pricing on both molecules nationwide from a LegitScript-verified operator — strong dollar-for-dollar value. Ro still earns a B — People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Gimme Care.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Gimme Care | Ro |
|---|---|---|
| Cost-Efficiency Index | 87/100 | 84/100 |
| Semaglutide / mo | $130/mo | Not disclosed |
| Tirzepatide / mo | $163/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,560 | — |
| Tirzepatide / yr (modeled) | $1,956 | — |
| Coverage | All 50 states | Multi-state |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #7 | #19 |
Gimme Care
87/100Where the value is
- Low published prices on both molecules — $130 semaglutide / $163 tirzepatide
- Nationwide all-50 availability with both molecules disclosed
- LegitScript-certified pharmacy behind the program
The tradeoffs
- Compounded only — no brand-name or oral options
- Lower-profile brand with a thinner public track record
Ro
84/100Where the value is
- Brand-name access and insurance support
- Oral options widen the formulary
- Polished, well-funded platform
The tradeoffs
- Does not publish compounded pricing up front — a blind spot in any cost model
- Premium positioning
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.